Devgen is a top 10 public agro biotech company with agricultural business units focused on developing and commercializing:

• a novel generation of biotech products to protect a wide spectrum of crops from damage incurred from pests;
• biotech traits and germplasm to meet the growing needs for high yielding, high quality hybrid rice and selected small grains in India and S.E. Asia;
• agro-chemical products with a safer and more environmental friendly profile to protect crops from damage inflicted by plant parasitic nematodes.

Devgen’s biopharmaceutical division develops a new class of preclinical drug candidates, based on novel therapeutic concepts, for treatment of a range of inflammatory and metabolic disease (diabetes, obesity) and arrhythmia.

Devgen has entered in partnerships with industry leaders in biotechnology and agro chemistry. Incorporated in 1997, Devgen has offices in Ghent (Belgium), Singapore and Hyderabad (India), with a total work force of about 100 people. Devgen is listed on Eurolist by Euronext Brussels (ticker: DEVG) since June 2005. For more information on Devgen, please visit the company’s web site: www.devgen.com.